Stock Chart

FULC

$10.73 -1.92%
Score: 54.5 HOLD
LEAPs: SELL $15
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $15
Premium: $5.48
Expiry: Jan 15, 2027
Target: $15
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $8.42 - $11.99 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.47
Vol: 0.62x (vs SPY: 0.5x | vs QQQ: 0.5x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About FULC - Fulcrum Therapeutics, Inc. Common Stock

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Key Statistics

Market Cap $708M

This FULC stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track FULC's price movements with trendlines, gamma walls, and key support/resistance levels.